FDA Approves Xyrem in Pediatric Patients with Narcolepsy
October 29th, 2018
The US Food and Drug Administration (FDA) approved Xyrem (sodium oxybate) for the treatment of cataplexy and excessive daytime sleepiness (EDS) in pediatric patients ages 7-17 with narcolepsy.
Read the full article here.
# # #
Date Created: October 29th, 2018
Last Updated: December 8th, 2020
